79 related articles for article (PubMed ID: 38446982)
1. BRAF V600E in a preclinical model of pleomorphic Xanthoastrocytoma: Analysis of the tumor microenvironment and immune cell infiltration dynamics
Canella A; Nazzaro M; Artomov M; Rao Venkata LP; Thomas D; Lyberger J; Ukhatov A; Xing YL; Miller K; Behbehani G; Amankulor NM; Petritsch CK; Rajappa P
Mol Ther Oncol; 2024 Jun; 32(2):200808. PubMed ID: 38784952
[TBL] [Abstract][Full Text] [Related]
2. A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Baik C; Cheng ML; Dietrich M; Gray JE; Karim NA
Adv Ther; 2024 May; ():. PubMed ID: 38698170
[TBL] [Abstract][Full Text] [Related]
3. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussein M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
Future Oncol; 2024 Feb; ():. PubMed ID: 38357801
[TBL] [Abstract][Full Text] [Related]
4. Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.
Schreck KC; Strowd RE; Nabors LB; Ellingson BM; Chang M; Tan SK; Abdullaev Z; Turakulov R; Aldape K; Danda N; Desideri S; Fisher J; Iacoboni M; Surakus T; Rudek MA; Bettegowda C; Grossman SA; Ye X
Clin Cancer Res; 2024 May; 30(10):2048-2056. PubMed ID: 38446982
[TBL] [Abstract][Full Text] [Related]
5. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692
[TBL] [Abstract][Full Text] [Related]
6. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
7. TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III
Boku S; Satake H; Ohta T; Mitani S; Kawakami K; Suzuki Y; Matsumoto T; Terazawa T; Yamazaki E; Hasegawa H; Ikoma T; Uemura M; Yamaguchi T; Naito A; Ishizuka Y; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Tsujinaka T; Kato T; Satoh T; Kagawa Y
Future Oncol; 2022 Dec; 18(38):4153-4160. PubMed ID: 36475784
[TBL] [Abstract][Full Text] [Related]
8. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic
Tahara M; Kiyota N; Imai H; Takahashi S; Nishiyama A; Tamura S; Shimizu Y; Kadowaki S; Ito KI; Toyoshima M; Hirashima Y; Ueno S; Sugitani I
Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
[No Abstract] [Full Text] [Related]
10. Dabrafenib plus Trametinib in Pediatric Glioma with
Bouffet E; Hansford JR; Garrè ML; Hara J; Plant-Fox A; Aerts I; Locatelli F; van der Lugt J; Papusha L; Sahm F; Tabori U; Cohen KJ; Packer RJ; Witt O; Sandalic L; Bento Pereira da Silva A; Russo M; Hargrave DR
N Engl J Med; 2023 Sep; 389(12):1108-1120. PubMed ID: 37733309
[TBL] [Abstract][Full Text] [Related]
11. Integrated molecular and clinical analysis of BRAF-mutant glioma in adults.
Schreck KC; Langat P; Bhave VM; Li T; Woodward E; Pratilas CA; Eberhart CG; Bi WL
NPJ Precis Oncol; 2023 Feb; 7(1):23. PubMed ID: 36854806
[TBL] [Abstract][Full Text] [Related]
12. BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis.
Garutti M; Bergnach M; Polesel J; Palmero L; Pizzichetta MA; Puglisi F
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612138
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib plus trametinib in patients with BRAF
Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V
Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.
Andrews LJ; Thornton ZA; Saincher SS; Yao IY; Dawson S; McGuinness LA; Jones HE; Jefferies S; Short SC; Cheng HY; McAleenan A; Higgins JPT; Kurian KM
Neuro Oncol; 2022 Apr; 24(4):528-540. PubMed ID: 34718782
[TBL] [Abstract][Full Text] [Related]
15. Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF
Schreck KC; Morin A; Zhao G; Allen AN; Flannery P; Glantz M; Green AL; Jones C; Jones KL; Kilburn LB; Nazemi KJ; Samuel D; Sanford B; Solomon DA; Wang J; Pratilas CA; Nicolaides T; Mulcahy Levy JM
Clin Cancer Res; 2021 Nov; 27(22):6197-6208. PubMed ID: 34433654
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
